Fragile X syndrome (FXS) is a neurodevelopmental disorder that causes
intellectual disability. It is a leading known genetic cause of autism. In
addition to cognitive, social, and communication deficits, humans with FXS
demonstrate abnormal sensory processing including sensory hypersensitivity.
Sensory hypersensitivity commonly manifests as auditory, tactile, or visual
defensiveness or avoidance. Clinical, behavioral, and electrophysiological
studies consistently show auditory hypersensitivity, impaired habituation to
repeated sounds, and reduced auditory attention in humans with FXS. Children
with FXS also exhibit significant visuospatial impairments. Studies in infants
and toddlers with FXS have documented impairments in processing texture-defined
motion stimuli, temporal flicker, perceiving ordinal numerical sequence, and the
ability to maintain the identity of dynamic object information during occlusion.
Consistent with the observations in humans with FXS, fragile X mental
retardation 1 (Fmr1) gene
knockout (KO) rodent models of FXS also show seizures, abnormal visual-evoked
responses, auditory hypersensitivity, and abnormal processing at multiple levels
of the auditory system, including altered acoustic startle responses. Among
other sensory symptoms, individuals with FXS exhibit tactile defensiveness.
Fmr1 KO mice also show impaired encoding of tactile
stimulation frequency and larger size of receptive fields in the somatosensory
cortex. Since sensory deficits are relatively more tractable from circuit
mechanisms and developmental perspectives than more complex social behaviors,
the focus of this review is on clinical, functional, and structural studies that
outline the auditory, visual, and somatosensory processing deficits in FXS. The
similarities in sensory phenotypes between humans with FXS and animal models
suggest a likely conservation of basic sensory processing circuits across
species and may provide a translational platform to not just develop biomarkers
but also to understand underlying mechanisms. We argue that preclinical studies
in animal models of FXS can facilitate the ongoing search for new therapeutic
approaches in FXS by understanding mechanisms of basic sensory processing
circuits and behaviors that are conserved across species.